# Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus

> **NCT05886088** · PHASE3 · NOT_YET_RECRUITING · sponsor: **EMS** · enrollment: 597 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** LID104
- **DRUG:** Dapagliflozin
- **DRUG:** Linagliptin

## Key facts

- **NCT ID:** NCT05886088
- **Lead sponsor:** EMS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-02
- **Primary completion:** 2026-05
- **Final completion:** 2027-01
- **Target enrollment:** 597 (ESTIMATED)
- **Last updated:** 2023-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05886088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05886088, "Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05886088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*